Metabolomics of pulmonary hypertension: from pathological mechanisms to therapeutic targets

doi:10.16352/j.issn.1001-6325.2024.08.1074

Abstract

Abstract: Pulmonary hypertension (PH) is a severe cardiovascular disease characterized primarily by pulmonary vascular remodeling. Patients with PH typically exhibit significant metabolic abnormalities including disruptions in energy metabolism, alterations in lipid and amino acids metabolism. These metabolic disturbances are closely linked to pathophysiological processes such as pulmonary vascular remodeling, endothelial dysfunction and right ventricular hypertrophy. In recent years, there has been rapid progress in the field of metabolomics related to PH. From the early identification of differential metabolic products to the current exploration of potential therapeutic targets, metabolomics has deepened the understanding of the pathogenesis of PH. These researches have accelerated the discovery and screening of potential therapeutic targets, with some findings already translated into clinical practice to support diagnosis, treatment and prognostic evaluation of PH.

Key words: metabolomics, pulmonary hypertension

CLC Number:

R543.2

DENG Yuanrui, WANG Xiaojian. Metabolomics of pulmonary hypertension: from pathological mechanisms to therapeutic targets[J]. Basic & Clinical Medicine, 2024, 44(8): 1074-1079.

References

[1] Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review[J]. JAMA, 2022, 327: 1379-1391.
[2] Mocumbi A, Humbert M, Saxena A, et al. Pulmonary hypertension[J]. Nat Rev Dis Primers, 2024, 10: 1. doi:10.1038/s41572-023-00486-7.
[3] D′Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry[J]. Ann Intern Med, 1991, 115: 343-349.
[4] Peacock AJ, Murphy NF, Mcmrray JJV, et al. An epidemiological study of pulmonary arterial hypertension[J]. Eur Respir J, 2007, 30: 104-109.
[5] Jing ZC, Xu XQ, Han ZY, et al. Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension[J]. Chest, 2007, 132: 373-379.
[6] Tuder RM, Davis LA, Graham BB. Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension[J]. Am J Respir Crit Care Med, 2012, 185: 260-266.
[7] Cottrill KA, Chan SY. Metabolic dysfunction in pulmonary hypertension: the expanding relevance of the Warburg effect[J]. Eur J Clin Invest, 2013, 43: 855-865.
[8] Sutendra G, Michelakis ED. The metabolic basis of pulmonary arterial hypertension[J]. Cell Metab, 2014, 19: 558-573.
[9] Pokharel MD, Marciano DP, Fu P, et al. Metabolic reprogramming, oxidative stress, and pulmonary hypertension[J]. Redox Biol, 2023, 64: 102797. doi:10.1016/j.redox.2023.102797.
[10] Pauling L, Robinson AB, Teranishi R, et al. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography[J]. Proc Natl Acad Sci USA, 1971, 68: 2374-2376.
[11] Bujak R, García A, Rupérez FJ, et al. Metabolomics reveals metabolite changes in acute pulmonary embolism[J]. J Proteome Res, 2014, 13: 805-816.
[12] Lewis GD, Ngo D, Henmes AR, et al. Metabolic profiling of right ventricular-pulmonary vascular function reveals circulating biomarkers of pulmonary hypertension[J]. J Am Coll Cardiol, 2016, 67: 174-189.
[13] Bujak R, Mateo J, Blanco I, et al. New biochemical insights into the mechanisms of pulmonary arterial hypertension in humans[J]. PLoS One, 2016, 11: e0160505. doi:10.1371/journal.pone.0160505.
[14] Rhodes CJ, Ghataorhe P, Wharton J, et al. Plasma metabolomics implicates modified transfer RNAs and altered bioenergetics in the outcomes of pulmonary arterial hypertension[J]. Circulation, 2017, 135: 460-475.
[15] Fessel JP, Hamid R, Wittmann BM, et al. Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals wides-pread metabolic reprogramming[J]. Pulm Circ, 2012, 2: 201-213.
[16] Zhao Y, Peng J, Lu C, et al. Metabolomic heterogeneity of pulmonary arterial hypertension[J]. PLoS One, 2014, 9: e88727. doi:10.1371/journal.pone.0088727.
[17] Zhao YD, Chu L, Lin K, et al. A biochemical approach to understand the pathogenesis of advanced pulmonary arterial hypertension: metabolomic profiles of arginine, sphingosine-1-phosphate, and heme of human lung[J]. PLoS One, 2015, 10: e0134958. doi:10.1371/journal.pone.0134958.
[18] Voelkel NF, Cool C, Lee SD, et al. Primary pulmonary hypertension between inflammation and cancer[J]. Chest, 1998, 114: 225S-230S.
[19] Rai PR, Cool CD, King JAC, et al. The cancer paradigm of severe pulmonary arterial hypertension[J]. Am J Respir Crit Care Med, 2008, 178: 558-564.
[20] Koppenol WH, Bounds PL, Dang CV. Otto Warburg′s contributions to current concepts of cancer metabolism[J]. Nat Rev Cancer, 2011, 11: 325-337.
[21] Zhao L, Ashek A, Wang L, et al. Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments[J]. Circulation, 2013, 128: 1214-1224.
[22] Hernandez SD, Sanders L, Freeman S, et al. Stable isotope metabolomics of pulmonary artery smooth muscle and endothelial cells in pulmonary hypertension and with TGF-beta treatment[J]. Sci Rep, 2020, 10: 413. doi:10.1038/s41598-019-57200-5.
[23] Cao Y, Zhang X, Wang L, et al. PFKFB3-mediated endothelial glycolysis promotes pulmonary hypertension[J]. Proc Natl Acad Sci USA, 2019, 116: 13394-13403.
[24] Wang L, Zhang X, Cao Y, et al. Mice with a specific deficiency of pfkfb3 in myeloid cells are protected from hypoxia-induced pulmonary hypertension[J]. Br J Pharmacol, 2021, 178: 1055-1072.
[25] Mey JT, Hari A, Axelrod CL, et al. Lipids and ketones dominate metabolism at the expense of glucose control in pulmonary arterial hypertension: a hyperglycaemic clamp and metabolomics study[J]. Eur Respir J, 2020, 55: 1901700. doi:10.1183/13993003.01700-2019.
[26] Legchenko E, Chouvarine P, Borchert P, et al. PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation[J]. Sci Transl Med, 2018, 10: eaao0303. doi:10.1126/scitranslmed.aao0303.
[27] Sutendra G, Bonnet S, Rochefort G, et al. Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension[J]. Sci Transl Med, 2010, 2: 44ra58. doi:10.1126/scitranslmed.3001327.
[28] Philip N, Pi H, Gadkari M, et al. Transpulmonary amino acid metabolism in the sugen hypoxia model of pulmonary hypertension[J]. Pulm Circ, 2023, 13: e12205. doi:10.1002/pul2.12205.
[29] Michelakis ED, Gurtu V, Webster L, et al. Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients[J]. Sci Transl Med, 2017, 9: eaao4583. doi:10.1126/scitranslmed.aao4583.
[30] Alotaibi M, Shao J, Pauciulo MW, et al. Metabolomic profiles differentiate scleroderma-PAH from idiopathic PAH and correspond with worsened functional capacity[J]. Chest, 2023, 163: 204-215.
[31] Simpson CE, Hemnes AR, Griffiths M, et al. Metabolo-mic differences in connective tissue disease-associated versus idiopathic pulmonary arterial hypertension in the PVDOMICS cohort[J]. Arthritis Rheumatol, 2023, 75: 2240-2251.
[32] Swietlik EM, Ghataorhe P, Zalewska KI, et al. Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension[J]. Eur Respir J, 2021, 57: 2003201. doi:10.1183/13993003.03201-2020.
[33] Brittain EL, Niswender K, Agrawal V, et al. Mechanistic phase II clinical trial of metformin in pulmonary arterial hypertension[J]. J Am Heart Assoc, 2020, 9: e018349. doi:10.1161/JAHA.120.018349.
[34] Gao X, Zhang Z, Li X, et al. Macitentan attenuates chronic mountain sickness in rats by regulating arginine and purine metabolism[J]. J Proteome Res, 2020, 19: 3302-3314.
[35] He YY, Yan Y, Chen JW, et al. Plasma metabolomics in the perioperative period of defect repair in patients with pulmonary arterial hypertension associated with congenital heart disease[J]. Acta Pharmacol Sin, 2022, 43: 1710-1720.
[36] He YY, Yan Y, Jiang X, et al. Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension[J]. Eur Respir J, 2020, 56: 2000522. doi:10.1183/13993003.00522-2020.
[37] Luo Y, Qi X, Zhang Z, et al. Inactivation of malic enzyme 1 in endothelial cells alleviates pulmonary hypertension[J]. Circulation, 2024, 149:1354-1371.
[38] Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Heart J, 2022, 43: 3618-3731.
[39] Harbaum L, Rhodes CJ, Otero NEZP, et al. The application of ‘omics’ to pulmonary arterial hypertension[J]. Br J Pharmacol, 2021, 178: 108-120.
[40] Guo TT, Deng YR, Huang X, et al. Untargeted metabolomics reveal the metabolic profile of normal pulmonary circulation[J]. Respir Med, 2023, 217: 107369. doi:10.1016/j.rmed.2023.107369.